Skip to main content

Can Neuroscience Improve Addiction Treatment and Policies?

Abstract

The main target of alcohol and other drug self-administration is the brain. For this reason understanding of brain mechanisms (i.e., neuroscience research) may offer important insights for creating effective prevention and treatment interventions, as well as fair and appropriate drug policies. Fair and appropriate drug policies (public laws and regulations) are expected to reduce the harms of drugs to the user and to society in general, while minimizing unintended but related policy “side effects.”

In this paper we explore how more informed understanding of neuroscience may help to improve the effectiveness and reduce the unintended side effects of contemporary drug policies. The article goes on to suggest some rational ways neuroscience may better inform and assist in policy decisions. We cover currently illegal drugs plus others such as alcohol and tobacco and touch on the new and emerging substances—legal highs.

References

  1. 1.

    Volkow ND, Fowler JS, Wang GJ, Baler R, Telang F. Imaging dopamine’s role in drug abuse and addiction. Neuropharmacology. 2009;56:3–8.

    CAS  Article  PubMed  Google Scholar 

  2. 2.

    Di Chiara G, Imperato A. Drugs abused by humans preferentially increase synaptic dopamine concentrations in the mesolimbic system of freely moving rats. Proc Natl Acad Sci U S A. 1988;85:5274–78.

    Article  PubMed  PubMed Central  Google Scholar 

  3. 3.

    Nestler EJ. Is there a common molecular pathway for addiction? Nat Neurosci. 2005;8:1445–9.

    CAS  Article  PubMed  Google Scholar 

  4. 4.

    Laruelle M. Imaging synaptic neurotransmission with in vivo binding competition techniques: a critical review. J Cereb Blood Flow Metab. 2000;20:423–51.

    CAS  Article  PubMed  Google Scholar 

  5. 5.

    Watson BJ, Taylor LG, Reid AG, Wilson SJ, Stokes PR, et al. Investigating expectation and reward in human opioid addiction with [11C]raclopride PET. Addict Biol. 5 July 2013; epub ahead of print.

    Google Scholar 

  6. 6.

    Nutt DJ, Lingford-Hughes A. Addiction: the clinical interface. Br J Pharmacol. 2008;154:397–405.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  7. 7.

    Thanos PK, Volkow ND, Freimuth P, Umegaki H, Ikari H, Roth G, et al. Overexpression of dopamine D2 receptors reduces alcohol self-administration. J Neurochem. 2001;78:1094–103. doi:10.

    CAS  Article  PubMed  Google Scholar 

  8. 8.

    Volkow ND, Wang GJ, Fowler JS, Tomasi D, Telang F. Addiction: beyond dopamine reward circuitry. Proc Natl Acad Sci U S A. 2011;108:15037–42.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  9. 9.

    Koob GF, Volkow ND. Neurocircuitry of addiction. Neuropsychopharmacology. 2009;35:217–38.

    Article  PubMed Central  Google Scholar 

  10. 10.

    Dalley JW, Fryer TD, Brichard L, Robinson ES, Theobald DE, et al. Nucleus accumbens D2/3 receptors predict trait impulsivity and cocaine reinforcement. Science. 2007;315:1267–70.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  11. 11.

    Volkow ND, Wang G-J, Fowler JS, Logan J, Gatley SJ, et al. Prediction of reinforcing responses to psychostimulants in humans by brain dopamine D2 receptor levels. Am J Psychiatry. 1999;156:1440–43.

    CAS  Article  PubMed  Google Scholar 

  12. 12.

    Martinez D, Saccone PA, Liu F, Slifstein M, Orlowska D, et al. Deficits in dopamine D(2) receptors and presynaptic dopamine in heroin dependence: commonalities and differences with other types of addiction. Biol Psychiatry. 2012;71:192–8.

    CAS  Article  PubMed  Google Scholar 

  13. 13.

    Volkow ND, Wang GJ, Begleiter H, Porjesz B, Fowler JS, et al. High levels of dopamine D2 receptors in unaffected members of alcoholic families: possible protective factors. Arch Gen Psychiatry. 2006;63:999–1008.

    CAS  Article  PubMed  Google Scholar 

  14. 14.

    Reid AG, Daglish MR, Kempton MJ, Williams TM, Watson B, et al. Reduced thalamic grey matter volume in opioid dependence is influenced by degree of alcohol use: a voxel-based morphometry study. J Psychopharmacol. 2008;22: 7–10.

    Article  PubMed  Google Scholar 

  15. 15.

    Volkow ND, Wang GJ, Fowler JS, Logan J, Gatley SJ, et al. Decreased striatal dopaminergic responsiveness in detoxified cocaine-dependent subjects. Nature. 1997;386:830–3.

    CAS  Article  PubMed  Google Scholar 

  16. 16.

    Nutt DJ, King LA, Phillips LD. Drug harms in the UK: a multicriteria decision analysis. Lancet. 2010;376:1558–65.

    Article  PubMed  Google Scholar 

  17. 17.

    Weissenborn R, Nutt DJ. Popular intoxicants: what lessons can be learned from the last 40 years of alcohol and cannabis regulation? J Psychopharmacol. 2012;26:213–20.

    Article  PubMed  Google Scholar 

  18. 18.

    Carter LP, Stitzer ML, Henningfield JE, O’Connor RJ, Cummings KM, Hatsukami DK. Abuse liability assessment of tobacco products including potential reduced exposure products. Cancer Epidemiol Biomarkers Prev. 2009;18:3241–62.

    Article  PubMed  PubMed Central  Google Scholar 

  19. 19.

    Krebs TS. Johansen PØ. Lysergic acid diethylamide (LSD) for alcoholism: meta-analysis of randomized controlled trials. J Psychopharmacol. 2012;26: 994–1002.

    Article  PubMed  Google Scholar 

  20. 20.

    Moreno FA, Wiegand CB, Taitano EK, Delgado PL. Safety, tolerability and efficacy of psilocybin in 9 patients with obsessive-compulsive disorder. J Clin. Psychiatry. 2006;67:1735–40.

    CAS  Article  PubMed  Google Scholar 

  21. 21.

    Mithoefer MC, Wagner MT, Mithoefer AT, Jerome L, Doblin R. The safety and efficacy of ±3,4-methylenedioxymethamphetamine-assisted psychotherapy in subjects with chronic, treatment-resistant posttraumatic stress disorder: the first randomized controlled pilot study. J Psychopharmacol. 2010;25:439–52.

    Article  PubMed  Google Scholar 

  22. 22.

    Nutt DJ, King LA, Nichols DE Effects of Schedule1 drug laws on neuroscience research and treatment innovation. Nature Rev Neurosci. 2013;14:577–85.

    CAS  Article  Google Scholar 

  23. 23.

    Carhart-Harris RL, Murphy K, Leech R, Erritzoe D, Wall MB, et al. The effects of acutely administered 3, 4-methylenedioxymethamphetamine on spontaneous brain function in healthy volunteers measured with arterial spin labelling and blood oxygen level-dependent resting-state functional connectivity. Biol Psychiatry. 2014; epub ahead of print.

    Google Scholar 

  24. 24.

    Carhart-Harris RL, Leech R, Hellyer PJ, Shanahan M, Feilding A, et al. The entropic brain: A theory of conscious states informed by neuroimaging research with psychedelic drugs. Front Hum Neurosci. 2014;8:20.

    Article  PubMed  PubMed Central  Google Scholar 

  25. 25.

    McLellan AT, Lewis DC, O’Brien CP, Kleber HD. Drug dependence, a chronic medical illness. JAMA. 2000;284:1689–95.

    CAS  Article  PubMed  Google Scholar 

  26. 26.

    McLellan AT, McKay JR, Forman R, Cacciola J, Kemp J. Reconsidering the evaluation of addiction treatment: from retrospective follow-up to concurrent recovery monitoring. Addiction. 2005;100:447–58.

    Article  PubMed  Google Scholar 

  27. 27.

    McLellan AT, Skipper GS, Campbell M, DuPont RL. Five year outcomes in a cohort study of physicians treated for substance use disorders in the United States. BMJ. 2008;337:a2038.

    Article  PubMed  PubMed Central  Google Scholar 

  28. 28.

    Mann K, Bladströam A, Torup L, Gual A, van den Brink W. Extending the treatment options in alcohol dependence: a randomized controlled study of as-needed nalmefene. Biol Psychiatry. 2013;73:706–13.

    CAS  Article  PubMed  Google Scholar 

  29. 29.

    Volkow ND, Wang GJ, Fowler JS, Tomasi, D. Addiction circuitry in the human brain. Annu Rev Pharmacol Toxicol. 2012;52:321–36.

    CAS  Article  PubMed  Google Scholar 

Download references

Author information

Affiliations

Authors

Corresponding author

Correspondence to David Nutt FMedSci.

Rights and permissions

Open Access  This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made.

The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder.

To view a copy of this licence, visit https://creativecommons.org/licenses/by/4.0/.

The Creative Commons Public Domain Dedication waiver (https://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and Permissions

About this article

Cite this article

Nutt, D., McLellan, A.T. Can Neuroscience Improve Addiction Treatment and Policies?. Public Health Rev 35, 5 (2013). https://doi.org/10.1007/BF03391704

Download citation

Key Words

  • Neuroscience
  • addiction treatment
  • drug policy
  • alcohol
  • tobacco